Ricardo Balderrama Ibarra

Dr. Ricardo Balderrama Ibarra

IMSS

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
EGEnrique Gutierrez
Enrique Gutierrez
Irving Sanchez-RodriguezIrving Sanchez-Rodriguez
Irving Sanchez-Rodriguez
Omar Diaz CazaresOmar Diaz Cazares
Omar Diaz Cazares
AVAdrián Valles
Adrián Valles
Ricardo Balderrama IbarraRicardo Balderrama Ibarra
Ricardo Balderrama Ibarra
ASAlexander Sun
Alexander Sun
Lung metastases are the second most common malignant neoplasms of the lung. It is estimated that 20–54% of cancer patients have lung metastases at some point during their disease course, and at least 50% of cancer-related deaths occur at this stage. Lung metastases are widely accepted to be oligometastatic when five lesions or less occur separately in up to three organs. Stereotactic body radiation therapy (SBRT) is a noninvasive, safe, and effective treatment for metastatic lung disease in carefully selected patients. There is no current consensus on the ideal dose and fractionation for SBRT in lung metastases, and it is the subject of study in ongoing clinical trials, which examines different locations in the lung (central and peripheral). This review discusses current indications, fractionations, challenges, and technical requirements for lung SBRT.